Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials

Core Insights - Pluri, Inc. has completed the first phase of its program with Resbiomed Technologies, focusing on developing placenta-derived biomaterials for regenerative medicine [1][2][3] Company Overview - Pluri is a biotechnology company specializing in scalable cell-based solutions and has a strong focus on regenerative medicine, foodtech, and agtech [7] - The company operates a contract development and manufacturing division, PluriCDMO™, which provides advanced manufacturing services [8] Collaboration Details - The partnership with Resbiomed aims to enhance the production of placenta-derived biomaterials, leveraging Pluri's proprietary processing capabilities [2][3] - The first phase involved initial process development and feasibility, with plans to advance to further phases focusing on process definition and manufacturing readiness [2][5] Market Potential - Human collagen and collagen-rich materials are in high demand due to their stringent quality requirements, and scalable production could expand access across various medical applications [4] - The collaboration is seen as a response to the growing demand for PluriCDMO services among companies developing next-generation cell and tissue-based technologies [5] Leadership Statements - The CEO of Pluri expressed confidence in the collaboration, highlighting its potential to accelerate programs and support commercialization efforts [6] - The CEO of Resbiomed emphasized the importance of partnering with an experienced manufacturer to ensure scalable supply and consistent quality [6]